Discovery STREAM

31. LC/MS/MS Analysis Of Coproporphyrin 1, Coproporphyrin 3 In Human Plasma 2/17/2025

    This innovative approach holds promise for reducing the need for extensive clinical drug-drug interaction studies, potentially streamlining the drug development process.

32. Can Kinetics Provide Detailed Information About Binding Interactions? 2/17/2022

    See the potential value kinetics brings to deepen the understanding of biological processes.

33. Meet Your Bioprocess Sidekick For Cell Culture Media Analysis 6/10/2022

    You need rapid and reliable nutrient profiles to make informed decisions, and waiting on that data has detrimental effects on your process. See how REBEL fills the gap.

34. Bio & The Business Of Aging with Life Biosciences' Jerry McLaughlin 9/7/2023

    Core to the clinical-stage biopharma Life Biosciences belief set is that "contrary to popular belief, aging is not caused by random wear and tear, but instead is caused by a discrete set of biological mechanisms that can be targeted therapeutically.”

35. A Derivatization-Free LCMS Assay For 4β-hydroxycholesterol 1/23/2025

    Learn about a novel LCMS assay for 4β-hydroxycholesterol, a key biomarker for CYP3A activity. This derivatization-free method offers a faster and more efficient approach for clinical studies.

36. Pragmatic Computational Biology with Andrew Satz 9/20/2023

    This week's guest on the Business of Biotech, EVQLV's Andrew Satz, says AI and ML in biopharma are like sex in high school. "Many of the people who say they're doing it really aren't, and the one who really are aren't talking about it," he says. So, when it comes to the computational biology buzz, what’s real? What’s hype? What’s yielding benefit and what’s merely vaporware?